How to cite item

Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.

   
@article{JTD10750,
	author = {Laura Mezquita and Benjamin Besse},
	title = {Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.},
	journal = {Journal of Thoracic Disease},
	volume = {8},
	number = {11},
	year = {2016},
	keywords = {},
	abstract = {Over the last few years, the introduction of several drugs acting against therapeutic targets has dramatically improved the prognosis of advanced non-small cell lung cancer (NSCLC), primarily for patients harboring epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. ALK rearrangements represent 3–7% of NSCLC, predominantly with adenocarcinoma histology and are mainly found in a light or non-smoker young population (1). Located on chromosome 2, they result in increased tyrosine kinase activity of the ALK receptor, promoting proliferation and tumor survival.},
	issn = {2077-6624},	url = {https://jtd.amegroups.org/article/view/10750}
}